Publicaciones en las que colabora con MARÍA HERNÁNDEZ SÁNCHEZ (34)

2023

  1. A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions

    Cancer Genetics, Vol. 272-273, pp. 16-22

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

2022

  1. TRAF3 alterations are frequent in del-3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 903-914

  2. Uso de las redes sociales Twitter e Instagram como herramientas docentes para la enseñanza de la genética clínica en la Universidad de Salamanca

    La necesidad de la transformación social desde la innovación docente y educativa (Aula Magna), pp. 261-279

  3. Uso de las redes sociales de Twitter e Instagram como herramientas docentes para la enseñanza de la genética clínica en la Universidad de Salamanca

    Educación y transferencia del conocimiento: propuesta de innovación para la mejora docente

2021

  1. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

  2. The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment

    Diagnostics, Vol. 11, Núm. 5

2020

  1. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612

  2. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

    International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792

2019

  1. 1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia

    Clinical and Experimental Medicine

  2. CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase

    Leukemia, Vol. 33, Núm. 2, pp. 518-558

  3. DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains

    Experimental Hematology, Vol. 72, pp. 9-13

2018

  1. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 3, pp. 633-642

  2. The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers only Prognostic Model and the MD Anderson Cancer Center Prognostic Index

    BioMed Research International, Vol. 2018

2017

  1. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts

    Leukemia Research, Vol. 56, pp. 82-87

  2. Analysis of the molecular heterogeneity and disease evolution in chronic lymphocytic leukemia by combining high-throughput genomic and transcriptomic technologies

    Analysis of the molecular heterogeneity and disease evolution in chronic lymphocytic leukemia by combining high-throughput genomic and transcriptomic technologies

  3. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Cancer Letters, Vol. 409, pp. 42-48

  4. Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL

    European Journal of Haematology, Vol. 98, Núm. 2, pp. 142-148

  5. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia

    British Journal of Cancer, Vol. 117, Núm. 2, pp. 256-265